` BFK (Pharmesis International Ltd) vs FTSE Straits Times Singapore Comparison - Alpha Spread

P
BFK
vs
F
FTSE Straits Times Singapore

Over the past 12 months, BFK has underperformed FTSE Straits Times Singapore, delivering a return of -40% compared to the FTSE Straits Times Singapore's 0% growth.

Stocks Performance
BFK vs FTSE Straits Times Singapore

Loading
BFK
FTSE Straits Times Singapore
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BFK vs FTSE Straits Times Singapore

Loading
BFK
FTSE Straits Times Singapore
Difference
www.alphaspread.com

Performance By Year
BFK vs FTSE Straits Times Singapore

Loading
BFK
FTSE Straits Times Singapore
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Pharmesis International Ltd vs Peers

FTSE Straits Times Singapore
BFK
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Pharmesis International Ltd
Glance View

Market Cap
10.5m SGD
Industry
Pharmaceuticals

Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

BFK Intrinsic Value
0.41 SGD
Undervaluation 19%
Intrinsic Value
Price
P
Back to Top